Histogen EBIT

Histogen (HSTO) currently reports a EBIT of $-12M as of September 2023. That compares with $-11M in the prior-year period — down 11.7% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Histogen's EBIT history and peer comparisons.

Histogen's EBIT decreased from $-11M to $-12M — a 11.7% year-over-year decrease (period ending September 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Histogen's EBIT of $-12M is lower than the Healthcare sector average of $23B. That is roughly 100.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Histogen reported $-12M in EBIT as of September 2023. That compares with $-11M in the prior-year period — down 11.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Histogen, and consider following HSTO for alerts when major investors trade the stock.